Abiopharma

🔍 Glaser Shelagh (Executive)

Company: PubMatic, Inc. (PUBM)

Report Date: 2026-05-29

Detailed Transactions and Holdings:

• Acquired 13,437 shares of Class A Common Stock (Direct)
  Date: 2026-05-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 21,502.00 | transaction_form_type: 4
• Acquired 15,839 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,839.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 9,971 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 3,466 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement.
• F2: The RSUs vest in full on the earliest to occur of (a) the first anniversary of the grant date, (b) immediately prior to the Company's annual meeting of stockholders in 2027, (c) the Reporting Person's death or disability, and (d) a change in control of the Issuer. Shares of the Issuer's Class A Common Stock will be delivered to the Reporting Person upon settlement of the RSUs.
• F3: RSUs do not expire; they either vest or are cancelled prior to vesting date.
• F4: The RSUs vest in full on the earliest to occur of (a) the first anniversary of the grant date, (b) immediately prior to the Company's annual meeting of stockholders in 2024, (c) the Reporting Person's death or disability, and (d) a change in control of the Issuer. The Reporting Person has elected to defer settlement of the RSUs until the earliest to occur of (i) the third anniversary of the grant date, (ii) the Reporting Person's death or disability, (iii) a change in control of the Issuer, and (iv) the Reporting Person's separation of service from the Issuer. Shares of the Issuer's Class A Common Stock will be delivered to the Reporting Person upon settlement of the RSUs.
• F5: Represents RSUs payable in lieu of annual cash fees for Board of Directors and committee service pursuant to the Reporting Person's election under the Issuer's non-employee director compensation policy. The RSUs vested in full on December 31, 2023. The Reporting Person elected to defer settlement of the RSUs until the earliest to occur of (a) the third anniversary of the Grant Date, (b) the Reporting Person's separation from service from the Issuer, and (c) a change in control of the Issuer. Shares of the Issuer's Class A Common Stock will be delivered to the Reporting Person upon settlement of the RSUs.